Please login to the form below

Not currently logged in
Email:
Password:

Belgium's Ablynx enters the US market

The biopharma firm's new subsidiary will be led by Daniel Schneider

AblynxBelgium biopharmaceutical company Ablynx has established a beachhead in the US, setting up a new subsidiary for that market.

Ablynx, Inc will be led by newly-appointed general manager Daniel Schneider, who will be based on the east coast.

One of his priorities will be to lead the commercialisation of Ablynx’s orphan drug caplacizumab.

The company is developing the ‘nanobody’ treatment for the rare blood disorder acquired thrombotic thrombocytopenic purpura (aTTP) and is on track for a regulatory submission in 2018.

Dr Edwin Moses, CEO of Ablynx, said: "The establishment of Ablynx, Inc. is an important milestone for the Company and confirms our commitment to becoming a fully integrated international biopharmaceutical company.

“[Dan] brings many years of experience in setting up commercial organisations and leading multiple successful product launches in the USA. We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab."

The drug recently marked a big win with positive phase III data showing it reduced the time to restoring normal platelet activity - the primary endpoint - and also cut the combined outcome measure of aTTP-related death, recurrence of aTTP and/or major thromboembolic events by 74% compared to placebo.

Commenting on his appointment, Mr Schneider added: "I am delighted to join Ablynx at this very important moment as the Company prepares for the potential launch of its first product. I look forward to building and leading the commercial activities in North America and contributing to the growth of the Company."

Schneider moves to Ablynx from BTG International, where he served as general manager of its specialty pharmaceutical business unit.

Prior to that he held a number of senior commercial with Sepracor, prior to its acquisition by Dainippon Sumitomo Pharma (DSP) and Solvay Pharmaceuticals, which is now part of AbbVie.

Article by
Dominic Tyer

16th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

R&D protocol amendments
Rethinking trials: the pros and cons of protocol amendments
Protocol amendments occur often and can be beneficial, but the steps involved can be complex...
Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...

Infographics